No profile data available.
uniQure N.v. (QURE) is a healthcare company in the blood disorder treatment drugs industry, based in Amsterdam, Netherlands, with about 221 full-time employees.
It reported revenue of $27.12 million for fiscal year 2024, up 71.2% from fiscal year 2023, and net income of -$239.56 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $3.70 million, up 61.8% from a year before. Its market capitalization was $1.57 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
uniQure reported $27.12 million in revenue for fiscal year 2024, up 71.2% from $15.84 million in fiscal year 2023. In Q3 2025 revenue was $3.70 million.
$1.57 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood disorder treatment drugs) include Incyte Corporation (INCY), Protagonist Therapeutics, Inc. (PTGX), Agios Pharmaceuticals, Inc. (AGIO), Ultragenyx Pharmaceutical Inc. (RARE).